Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study

Diabetologia

Volumn 55, Issue 9, 2012, Pages 2489-2493

  Nin, J W M ^a,b,c   Ferreira, I ^a,b,c   Schalkwijk, C G ^a,b   Jorsal, A ^d,e   Prins, M H ^c   Parving, H H ^f,g   Tarnow, L ^d   Rossing, P ^d   Stehouwer, C D A ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STENO DIABETES CENTER   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f University of Copenhagen   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

Author keywords

All cause mortality; Cardiovascular disease; High mobility group box 1; Type 1 diabetes mellitus

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN;

ALBUMINURIA; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HMGB1 PROTEIN; HUMANS; INCIDENCE; INFLAMMATION; MALE; NETHERLANDS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84866080667     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2622-1     Document Type: Article

References (10)

1. Nin JW, Jorsal A, Ferreira I et al (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 34:442-447
2. Li W, Sama AE, Wang H (2006) Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 6:130-135
3. Hu X, Jiang H, Bai Q et al (2009) Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 406:139-142
4. Yan XX, Lu L, Peng WH et al (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:544-548
5. Wang LJ, Lu L, Zhang FR, Chen QJ, de Catherina R, Shen WF (2011) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 13:440-449
6. Kalinina N, Agrotis A, Antropova Y et al (2004) Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 24:2320-2325
7. Inoue K, Kawahara K, Biswas KK et al (2007) HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16:136-143
8. Kanellakis P, Agrotis A, Kyaw TS et al (2011) High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 31:313-319
9. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367-388
10. Nin JW, Ferreira I, Schalkwijk CG et al (2012) Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria, but not with cardiovascular disease in type 1 diabetes. Eur J Endocrinol 166:325-332